InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025)
InMed Pharmaceuticals' (INM) quarterly EBITDA Margin came in at 256.36% in Q4 2025, down 5360.0% year-on-year from 4.87% in Q4 2024, and down 57.72% quarter-over-quarter from 162.54% in Q3 2025.
InMed Pharmaceuticals (INM) EBITDA Margin (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' EBITDA Margin history runs 5 years deep, the most recent figure standing at 256.36% for Q4 2025.
- On a quarterly basis, EBITDA Margin fell 5360.0% year-over-year to 256.36% in Q4 2025; TTM through Dec 2025 was 184.16%, a 2134.0% decrease from a year earlier, with the FY2025 full-year figure at 160.77%, up 1750.0% from the prior year.
- EBITDA Margin declined to 256.36% in Q4 2025 per INM's latest filing, from 162.54% in the prior quarter.
- Across five years, EBITDA Margin topped out at 20.99% in Q2 2023 and bottomed at 1626.64% in Q4 2021.
- The 5-year median for EBITDA Margin is 202.75% (2024), against an average of 420.14%.
- Across the five-year window, EBITDA Margin soared 124562 bps in 2023 and slumped 13755 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 1626.64% in 2021, then surged by 71 bps to 471.26% in 2022, then surged by 72 bps to 132.64% in 2023, then plunged by 53 bps to 202.75% in 2024, then dropped by 26 bps to 256.36% in 2025.
- Per Business Quant, the three latest INM EBITDA Margin figures stand at 256.36% (Q4 2025), 162.54% (Q3 2025), and 189.17% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -256.36% |
| Sep 30, 2025 | -162.54% |
| Jun 30, 2025 | -189.17% |
| Mar 31, 2025 | -151.24% |
| Dec 31, 2024 | -202.75% |
| Sep 30, 2024 | -137.19% |
| Jun 30, 2024 | -158.54% |
| Mar 31, 2024 | -157.28% |
| Dec 31, 2023 | -132.64% |
| Sep 30, 2023 | -296.37% |
| Jun 30, 2023 | -20.99% |
| Mar 31, 2023 | -208.13% |
| Dec 31, 2022 | -471.26% |
| Sep 30, 2022 | -1,114.75% |
| Jun 30, 2022 | -1,266.61% |
| Mar 31, 2022 | -589.94% |
| Dec 31, 2021 | -1,626.64% |